title: The Possibly Reversible Isotretinoin Effect of Decreased Ovarian Reserve in Sprague-Dawley Albinos: Part I, Biochemical Analyses.
abstract: BACKGROUND
  The study aims to determine the detrimental effects of 7.5 mg/kg/day isotretinoin treatment on the anti-Mullerian hormone (AMH) levels in an experimental study to see whether the effects on ovarian reserve are reversible.
  
  
  METHODS
  Blood was sampled in 16 Sprague-Dawley albinos before any treatment to see baseline AMH levels. Then, the rats were randomly divided into 2 groups. Control group received only 1.0 ml soybean oil per oral for 30 days, whereas the study group received 7.5 mg/kg/day isotretinoin suspended in soybean oil. AMH levels were measured at the 30th day - immediately after the last medication - and on 60th day - 1 month after the last medication.
  
  
  RESULTS
  The mean values of AMH levels were 8.16 ± 1.47, 6.95 ± 1.87, 6.27 ± 0.71 and 8.20 ± 1.48, 6.56 ± 1.45, 7.07 ± 0.96 ng/ml before, immediately after and 1 month after the last medication in the control and isotretinoin treatment group, respectively. The mean AMH levels significantly decreased (p = 0.02) immediately after isotretinoin administration. The mean AMH levels 1 month after the last dose of isotretinoin therapy were higher than the levels immediately after the medication; however, the difference was not statistically significant.
  
  
  CONCLUSIONS
  This study indicates that exposure to isotretinoin is responsible for decreased AMH levels in experimental rat model and this effect seems to be reversible.
authors.affiliation: Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey.
authors.forename: Elmas
authors.initials: E
authors.lastname: Korkmaz
authors.forename: Nilufer
authors.initials: N
authors.lastname: Cetinkaya
authors.forename: Murat
authors.initials: M
authors.lastname: Oz
authors.forename: Emre
authors.initials: E
authors.lastname: Ozgu
authors.forename: Sevda
authors.initials: S
authors.lastname: Bas
authors.forename: Mehmet
authors.initials: M
authors.lastname: Isikalan
authors.forename: Umran
authors.initials: U
authors.lastname: Buyukkagnici
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Caydere
authors.forename: Sema
authors.initials: S
authors.lastname: Hucumenoglu
authors.forename: Tayfun
authors.initials: T
authors.lastname: Gungor
mesh_terms: D000284:Administration, Oral; D000818:Animals; D054304:Anti-Mullerian Hormone / Q000097:blood*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D015474:Isotretinoin / Q000008:administration & dosage*; D023421:Models, Animal; D065851:Ovarian Reserve / Q000187:drug effects*; D010053:Ovary / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D003879:Dermatologic Agents; D054304:Anti-Mullerian Hormone; D015474:Isotretinoin